Filing Flows

Filing Flows › Revolution Medicines (RVMD) › Next earnings date

Revolution Medicines (RVMD) earnings: beat the estimate

Revolution Medicines (RVMD) reported on Nov 4, 2026 and beat the EPS estimate: −$1.90 against −$2.38 (+20.2%). Revenue was $198M for Q3 2026. It beat the EPS estimate in 20% of the quarters on record.

Last result+20.2% vs estimate
Beat rate20%

The last report

Revolution Medicines reported revenue of $198M for the third quarter 2026, net loss $407M. How it makes money → · Every quarter →

Revolution Medicines: EPS against the estimate, last 5 reportsRevolution Medicines: EPS against the estimate, last 5 reportsEstimateReported−$1.41−$1.61Nov 25−$1.56−$1.86Feb 26−$1.84−$2.29May 26−$2.06−$3.06Aug 26−$2.38−$1.90Nov 26
Latest (Nov 26): Estimate −$2.38, Reported −$1.90.

Revolution Medicines' latest quarter

Revolution Medicines, Q3 2026: revenue $198M, operating margin -188.9%, net loss $407M, operating cash flow −$416M. The chart follows the revenue to costs, profit and cash.

Questions

Did Revolution Medicines beat earnings?

Revolution Medicines (RVMD) reported on Nov 4, 2026 and beat the EPS estimate: −$1.90 against −$2.38 (+20.2%).

When does RVMD report earnings?

The next date is not set yet.

Does Revolution Medicines usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.